Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: A dose-finding study

Alessandra Fabi, Alessandra Mirri, Alessandra Felici, Antonello Vidiri, Andrea Pace, Emanuele Occhipinti, Francesco Cognetti, Giorgio Arcangeli, Bruno Iandolo, Maria Antonia Carosi, Giulio Metro, Carmine Maria Carapella

Research output: Contribution to journalArticle

Abstract

In patients with newly diagnosed glioblastoma multiforme (GBM), concurrent chemo-radiotherapy with temozolomide is the new standard of care. In the present phase I study we investigated the association of gemcitabine, a cell-cycle antimetabolite with radiosensitizing properties, with radiotherapy (RT) in the first line treatment. Gemcitabine was delivered at a fixed dose-rate of 10 mg/m2/ min weekly for 6 weeks starting 24-72 h prior to, and then concomitantly with RT (2.0 Gy per fraction, total dose 60 Gys). The primary end-point was the identification of dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). Planned dose levels of gemcitabine started from 200 mg/m2/weekly (level 1), with sequential dose escalations of 25 mg/m2. Ten patients were enrolled, all with evaluable disease after surgery. Six patients were male, median age was 55 years (44-75), and median baseline Karnofsky performance status was 85 (70-100). Four patients entered level 1, one patient being excluded from the study because of early disease progression. At this level, two of three patients developed progressive neurological deterioration, potentially related to the experimental treatment. On this basis gemcitabine dose was prudentially reduced to 175 mg/m2/weekly in the subsequent step (level -1). No DLT was encountered in the six patients enrolled at this level. Interestingly, at this dose only two grade three toxicities (one neutropenia and one raise in serum transaminases) were reported. Thus, fixed dose-rate gemcitabine at 175 mg/m2/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalJournal of Neuro-Oncology
Volume87
Issue number1
DOIs
Publication statusPublished - Mar 2008

Fingerprint

gemcitabine
Glioblastoma
Radiotherapy
temozolomide
Karnofsky Performance Status
Antimetabolites
Maximum Tolerated Dose
Standard of Care
Transaminases
Neutropenia
Disease Progression
Cell Cycle

Keywords

  • Chemo-radiotherapy
  • Gemcitabine
  • Glioblastoma multiforme
  • PhaseI study

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma : A dose-finding study. / Fabi, Alessandra; Mirri, Alessandra; Felici, Alessandra; Vidiri, Antonello; Pace, Andrea; Occhipinti, Emanuele; Cognetti, Francesco; Arcangeli, Giorgio; Iandolo, Bruno; Carosi, Maria Antonia; Metro, Giulio; Carapella, Carmine Maria.

In: Journal of Neuro-Oncology, Vol. 87, No. 1, 03.2008, p. 79-84.

Research output: Contribution to journalArticle

@article{a54be67486284c60bcccccd2d9532140,
title = "Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: A dose-finding study",
abstract = "In patients with newly diagnosed glioblastoma multiforme (GBM), concurrent chemo-radiotherapy with temozolomide is the new standard of care. In the present phase I study we investigated the association of gemcitabine, a cell-cycle antimetabolite with radiosensitizing properties, with radiotherapy (RT) in the first line treatment. Gemcitabine was delivered at a fixed dose-rate of 10 mg/m2/ min weekly for 6 weeks starting 24-72 h prior to, and then concomitantly with RT (2.0 Gy per fraction, total dose 60 Gys). The primary end-point was the identification of dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). Planned dose levels of gemcitabine started from 200 mg/m2/weekly (level 1), with sequential dose escalations of 25 mg/m2. Ten patients were enrolled, all with evaluable disease after surgery. Six patients were male, median age was 55 years (44-75), and median baseline Karnofsky performance status was 85 (70-100). Four patients entered level 1, one patient being excluded from the study because of early disease progression. At this level, two of three patients developed progressive neurological deterioration, potentially related to the experimental treatment. On this basis gemcitabine dose was prudentially reduced to 175 mg/m2/weekly in the subsequent step (level -1). No DLT was encountered in the six patients enrolled at this level. Interestingly, at this dose only two grade three toxicities (one neutropenia and one raise in serum transaminases) were reported. Thus, fixed dose-rate gemcitabine at 175 mg/m2/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress.",
keywords = "Chemo-radiotherapy, Gemcitabine, Glioblastoma multiforme, PhaseI study",
author = "Alessandra Fabi and Alessandra Mirri and Alessandra Felici and Antonello Vidiri and Andrea Pace and Emanuele Occhipinti and Francesco Cognetti and Giorgio Arcangeli and Bruno Iandolo and Carosi, {Maria Antonia} and Giulio Metro and Carapella, {Carmine Maria}",
year = "2008",
month = "3",
doi = "10.1007/s11060-007-9489-x",
language = "English",
volume = "87",
pages = "79--84",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma

T2 - A dose-finding study

AU - Fabi, Alessandra

AU - Mirri, Alessandra

AU - Felici, Alessandra

AU - Vidiri, Antonello

AU - Pace, Andrea

AU - Occhipinti, Emanuele

AU - Cognetti, Francesco

AU - Arcangeli, Giorgio

AU - Iandolo, Bruno

AU - Carosi, Maria Antonia

AU - Metro, Giulio

AU - Carapella, Carmine Maria

PY - 2008/3

Y1 - 2008/3

N2 - In patients with newly diagnosed glioblastoma multiforme (GBM), concurrent chemo-radiotherapy with temozolomide is the new standard of care. In the present phase I study we investigated the association of gemcitabine, a cell-cycle antimetabolite with radiosensitizing properties, with radiotherapy (RT) in the first line treatment. Gemcitabine was delivered at a fixed dose-rate of 10 mg/m2/ min weekly for 6 weeks starting 24-72 h prior to, and then concomitantly with RT (2.0 Gy per fraction, total dose 60 Gys). The primary end-point was the identification of dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). Planned dose levels of gemcitabine started from 200 mg/m2/weekly (level 1), with sequential dose escalations of 25 mg/m2. Ten patients were enrolled, all with evaluable disease after surgery. Six patients were male, median age was 55 years (44-75), and median baseline Karnofsky performance status was 85 (70-100). Four patients entered level 1, one patient being excluded from the study because of early disease progression. At this level, two of three patients developed progressive neurological deterioration, potentially related to the experimental treatment. On this basis gemcitabine dose was prudentially reduced to 175 mg/m2/weekly in the subsequent step (level -1). No DLT was encountered in the six patients enrolled at this level. Interestingly, at this dose only two grade three toxicities (one neutropenia and one raise in serum transaminases) were reported. Thus, fixed dose-rate gemcitabine at 175 mg/m2/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress.

AB - In patients with newly diagnosed glioblastoma multiforme (GBM), concurrent chemo-radiotherapy with temozolomide is the new standard of care. In the present phase I study we investigated the association of gemcitabine, a cell-cycle antimetabolite with radiosensitizing properties, with radiotherapy (RT) in the first line treatment. Gemcitabine was delivered at a fixed dose-rate of 10 mg/m2/ min weekly for 6 weeks starting 24-72 h prior to, and then concomitantly with RT (2.0 Gy per fraction, total dose 60 Gys). The primary end-point was the identification of dose-limiting toxicity (DLT), and maximum tolerated dose (MTD). Planned dose levels of gemcitabine started from 200 mg/m2/weekly (level 1), with sequential dose escalations of 25 mg/m2. Ten patients were enrolled, all with evaluable disease after surgery. Six patients were male, median age was 55 years (44-75), and median baseline Karnofsky performance status was 85 (70-100). Four patients entered level 1, one patient being excluded from the study because of early disease progression. At this level, two of three patients developed progressive neurological deterioration, potentially related to the experimental treatment. On this basis gemcitabine dose was prudentially reduced to 175 mg/m2/weekly in the subsequent step (level -1). No DLT was encountered in the six patients enrolled at this level. Interestingly, at this dose only two grade three toxicities (one neutropenia and one raise in serum transaminases) were reported. Thus, fixed dose-rate gemcitabine at 175 mg/m2/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress.

KW - Chemo-radiotherapy

KW - Gemcitabine

KW - Glioblastoma multiforme

KW - PhaseI study

UR - http://www.scopus.com/inward/record.url?scp=38649107067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649107067&partnerID=8YFLogxK

U2 - 10.1007/s11060-007-9489-x

DO - 10.1007/s11060-007-9489-x

M3 - Article

C2 - 17987263

AN - SCOPUS:38649107067

VL - 87

SP - 79

EP - 84

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -